P600 Serologic response to COVID-19 vaccines in IBD patients: a prospective study

P602 Tofacitinib treatment prevents post-operative recurrence of Crohn’s Disease modeled by ileocecal resection in HLA-B27 transgenic rats.

P607 Efficacy and safety of tofacitinib in Ulcerative Colitis patients with extraintestinal manifestations in OCTAVE Open

P610 Safety of COVID-19 vaccine in patients with Inflammatory Bowel Disease: preliminary data of a national study (ESCAPE-IBD)

P616 Safety of COVID-19 vaccines in patients with IBD

P641 Implementation and short-term adverse events of anti-SARS-CoV-2 vaccines in Inflammatory Bowel Disease patients: an international web-based survey

P694 COVID-19 vaccination rate and willingness of an additional dose among inflammatory bowel disease patients receiving biologic therapy.

DOP26 COVID-19 vaccine effectiveness in Inflammatory Bowel Disease patients on tumor-necrosis factor inhibitors: Real world data from a mass-vaccination campaign

DOP80 Integrated tissue transcriptomic and serum proteomic interrogation reveals biomarkers for endoscopic improvement and histologic remission after JAK3/TEC inhibition with ritlecitinib (PF-06651600) ...

OP21 COVID-19 vaccine-induced antibody responses are impaired in Inflammatory Bowel Disease patients treated with infliximab, ustekinumab or tofacitinib, but not thiopurines or vedolizumab

Industry Exhibition

... MSD 9 Nestlé Health Science 26 Nordic Bioscience 1 Nutritional Therapy for IBD 33 Pfizer 21 Pharmacosmos ...

Corporate Members

... encouraging young physicians in their careers and promoting innovative scientific research in IBD in Europe: 2020 ECCO Multi-Year Research Grant (supported by Pfizer) 2018 ECCO-Pfizer Research Grant ...

Corporate Members 2022

... encouraging young physicians in their careers and promoting innovative scientific research in IBD in Europe: 2020 ECCO Multi-Year Research Grant (supported by Pfizer) 2018 ECCO-Pfizer Research Grant ...

Search